Glaukos has been granted a patent for an implant that releases axitinib, a small molecule tyrosine kinase inhibitor, from a bioerodible polyester polymer blend. The implant is designed for intravitreal injection to treat ophthalmic conditions like neovascular age-related macular degeneration and diabetic macular edema. GlobalData’s report on Glaukos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Glaukos, Customized implants was a key innovation area identified from patents. Glaukos's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Implant for sustained release of axitinib for ophthalmic treatment
A recently granted patent (Publication Number: US11883525B2) discloses an implant containing axitinib and a bioerodible polyester polymer blend comprising at least two polymers. The blend includes an acid or ester end group polylactic acid (PLA) and an acid or ester end group poly-D,L-lactide-co-glycolide (PLGA), with specific inherent viscosities and ratios. The implant's composition allows for the controlled release of axitinib within a specified range of 5 to 80 percent (w/w) and tailored release rates ranging from 10 ng/day to 10 mg/day.
Furthermore, the patent details various embodiments of the implant, including specific ratios of PLA to PLGA, release durations of axitinib from at least six months to one year post-implantation in the vitreous humor of an eye, and criteria for burst release percentages over a 24-hour period. The implant design aims to achieve a substantially constant release rate of axitinib over an initial three-month period, following the end of the burst release or lag phase, ensuring therapeutic efficacy while minimizing potential side effects. The patent emphasizes the importance of achieving near-zero order or pseudo-zero order release kinetics during the initial three-month period to optimize the drug's therapeutic benefits in treating eye conditions.
To know more about GlobalData’s detailed insights on Glaukos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
